Synta Pharmaceuticals Corp (SNTA.W)
4 Dec 2013
|Market Cap (Mil.):||$425.49|
|Shares Outstanding (Mil.):||83.10|
- Shares of Synta Pharmaceuticals Corp fell 21 percent on Monday after updated data from a mid-stage lung cancer trial showed that its drug had less clinical benefit than previously reported.
(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s)
- Synta Pharmaceuticals Corp shares soared as much as 47 percent in heavy trading after the company said preliminary results from a mid-stage study of its drug ganetespib in breast cancer patients supported an expansion of the study.
|Johnson & Johnson (JNJ.N)||$93.63||-0.34|
|Amgen, Inc. (AMGN.OQ)||$112.92||-0.53|
|Abbott Laboratories (ABT.N)||$37.36||-0.24|
|Infinity Pharmaceuticals Inc. (INFI.OQ)||$14.50||+0.15|
|Novartis AG (NOVN.VX)||CHF70.75||+0.10|
|Kyowa Hakko Kirin Co Ltd (4151.T)||¥1,146||-22.00|
|OXiGENE Inc (OXGN.OQ)||$2.59||+0.01|
|Sanofi SA (SASY.PA)||€74.70||-0.22|
|Wyeth Limited (WLED.NS)||Rs828.30||-22.50|
|Curis, Inc. (CRIS.OQ)||$3.33||-0.10|
Earnings vs. Estimates
Analyst Research Reports
Provider: ValuEngine, Inc.
Provider: Thomson Reuters Stock Report
Provider: S&P Capital IQ Quantitative Report
Provider: Pechala's Reports
Provider: Ford Investor Services, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.